Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

However, I was fascinated to discover that viruses like hepatitis B hijack epigenetic mechanisms, even using human DNA-packaging proteins to regulate their activity.” Not long after, study first ...

However, I was fascinated to discover that viruses like hepatitis B hijack epigenetic mechanisms, even using human DNA-packaging proteins to regulate their activity." Not long after, Dr. Prescott ...

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...

Worldwide, hepatitis B is thought to be the second deadliest infection; about 5% of the global population are infection and it can lead to liver cancer. | Microbiology ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Seroconversion from HBeAg to anti-HBe is usually associated with serum HBV DNA undetectable by hybridization technology and remission of liver disease. Nevertheless, a certain proportion of anti ...

Compensated If HBV DNA ≥2000 IU/ml, treat If HBV DNA is 1–2000 IU/ml, treat if ALT is elevated Decompensated If HBV DNA is detectable, treat and refer for liver transplantation If HBV DNA is ...

ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B executing on schedule with completion of first dose administration for cohort 1 (n=3 patients) PBGENE-HBV, the first LNP gene editing ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...